bPiDl hydrate, >=98% (HPLC)

Code: SML0182-10MG D2-231

Not available outside of the UK & Ireland.

Application

bPiDl hydrate may be used to study nicotinic receptor-mediated signaling.

Biochem/physiol Actions

bPiDI is an α6β2-specific...


 Read more

Your Price
$130.45 10MG
Discontinued

Not available outside of the UK & Ireland.

Application

bPiDl hydrate may be used to study nicotinic receptor-mediated signaling.

Biochem/physiol Actions

bPiDI is an α6β2-specific antagonist that inhibits nicotine-evoked and endogenous dopamine release from rat striatal slices (IC50 = 150 nM, Imax = 55%). bPiDI treatment decreases nicotine self-administration, and nicotine-induced locomotor activity in rats.

Features and Benefits

This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

10 mg in glass bottle

assay≥98% (HPLC)
colorwhite to tan
formpowder
InChI keyILAREMIWZYIULF-UHFFFAOYSA-L
InChI1S/C22H34N2.2HI.H2O/c1-21-13-11-17-23(19-21)15-9-7-5-3-4-6-8-10-16-24-18-12-14-22(2)20-24;;;/h11-14,17-20H,3-10,15-16H2,1-2H3;2*1H;1H2/q+2;;;/p-2
Quality Level100
SMILES stringO.[I-].[I-].Cc1ccc[n+](CCCCCCCCCC[n+]2cccc(C)c2)c1
solubilityH2O: ≥10 mg/mL
storage temp.2-8°C
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN
GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.